A detailed history of Mitsubishi Ufj Kokusai Asset Management Co., Ltd. transactions in Cure Vac N.V. stock. As of the latest transaction made, Mitsubishi Ufj Kokusai Asset Management Co., Ltd. holds 79,962 shares of CVAC stock, worth $303,055. This represents 0.0% of its overall portfolio holdings.

Number of Shares
79,962
Previous 87,514 8.63%
Holding current value
$303,055
Previous $297,000 20.88%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$2.74 - $3.79 $20,692 - $28,622
-7,552 Reduced 8.63%
79,962 $235,000
Q2 2024

Aug 12, 2024

BUY
$2.31 - $4.99 $104,698 - $226,166
45,324 Added 107.43%
87,514 $297,000
Q1 2024

May 09, 2024

SELL
$2.94 - $4.34 $5,680 - $8,384
-1,932 Reduced 4.38%
42,190 $127,000
Q4 2023

Feb 08, 2024

BUY
$3.96 - $6.41 $54,200 - $87,733
13,687 Added 44.97%
44,122 $185,000
Q3 2023

Nov 07, 2023

BUY
$6.5 - $10.77 $10,627 - $17,608
1,635 Added 5.68%
30,435 $207,000
Q2 2023

Aug 09, 2023

SELL
$6.69 - $12.25 $26,927 - $49,306
-4,025 Reduced 12.26%
28,800 $300,000
Q1 2023

May 08, 2023

BUY
$6.38 - $12.5 $12,913 - $25,300
2,024 Added 6.57%
32,825 $228,000
Q4 2022

Feb 07, 2023

BUY
$5.75 - $8.5 $107,461 - $158,856
18,689 Added 154.3%
30,801 $185,000
Q3 2022

Nov 01, 2022

SELL
$7.48 - $15.24 $291 - $594
-39 Reduced 0.32%
12,112 $95,000
Q2 2022

Aug 04, 2022

BUY
$13.18 - $19.41 $56,186 - $82,744
4,263 Added 54.04%
12,151 $165,000
Q1 2022

May 09, 2022

BUY
$14.73 - $35.25 $13,050 - $31,231
886 Added 12.65%
7,888 $155,000
Q4 2021

Feb 07, 2022

BUY
$33.72 - $48.22 $146,176 - $209,033
4,335 Added 162.54%
7,002 $247,000
Q2 2021

Aug 06, 2021

BUY
$56.91 - $127.53 $151,778 - $340,122
2,667 New
2,667 $196,000

Others Institutions Holding CVAC

About CureVac N.V.


  • Ticker CVAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,467,008
  • Market Cap $710M
  • Description
  • CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...
More about CVAC
Track This Portfolio

Track Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Portfolio

Follow Mitsubishi Ufj Kokusai Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Kokusai Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mitsubishi Ufj Kokusai Asset Management Co., Ltd. with notifications on news.